Nephrotic syndrome after Infliximab treatment in a patient with Ulcerative Colitis

Journal of Gastrointestinal and Liver Diseases

Volumn 24, Issue 2, 2015, Pages 249-251

  Dumitrescu, Gabriela ^a,b   Dahan, Karine ^c   Treton, Xavier ^a   Corcos, Olivier ^a   Bouhnik, Yoram ^a   Stefanescu, Carmen ^a  

^a BEAUJON HOSPITAL   (France)

^b GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c HÔPITAL TENON   (France)

Author keywords

Infliximab; Nephrotic syndrome; Ulcerative colitis

Indexed keywords

ALBUMIN; ANTICOAGULANT AGENT; CALCIUM; CREATININE; INFLIXIMAB; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; POTASSIUM; RAMIPRIL; RITUXIMAB; UREA; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; TUMOR NECROSIS FACTOR;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CASE REPORT; COLONOSCOPY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; MALE; MICROSCOPY; MIDDLE AGED; NEPHROTIC SYNDROME; PROTEINURIA; RECTUM HEMORRHAGE; TREATMENT FAILURE; ULCERATIVE COLITIS; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COLITIS, ULCERATIVE; DRUG SUBSTITUTION; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; IMMUNOLOGY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; DRUG SUBSTITUTION; GASTROINTESTINAL AGENTS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; INFLIXIMAB; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84981716452     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.242.infx     Document Type: Article

References (17)

1. Iizuka M, Konno S, Horie Y, Itou H, Shindo K, Watanabe S. Infliximab as a treatment for systemic amyloidosis associated with Crohn’s disease. Gut 2006; 55: 744-745. doi: 10.1136/gut.2005.087577
2. Iizuka M, Sagara S, Etou T. Efficacy of scheduled infliximab maintenance therapy on systemic amyloidosis associated with crohn’s disease. Inflamm Bowel Dis 2011; 17: E67-E68. doi: 10.1002/ibd.21720
3. Boscá MM, Pérez-Baylach CM, Solis MA, et al. Secondary amyloidosis in Crohn’s disease: treatment with tumour necrosis factor inhibitor. Gut 2006; 55: 294-295. doi: 10.1136/gut.2005.082057
4. Park YK, Han DS, Eun CS. Systemic amyloidosis with Crohn’s disease treated with infliximab. Inflamm Bowel Dis 2008; 14: 431-432. doi: 10.1002/ibd.20289
5. Fidalgo C, Calado J, Cravo M. Secondary amyloidosis in a patient with long duration Crohn’s disease treated with infliximab. BioDrugs 2010; 24 Suppl 1: 15-17. doi: 10.2165/11586250-000000000-00000
6. Cabezuelo JB, Egea JP, Ramos F, Torrella E, Muray S, Alcazar C. Infliximab in the treatment of amyloidosis secondary to Crohn’s disease. Nefrologia 2012; 32: 385-388. doi: 10.3265/Nefrologia.pre2012.Feb.11332
7. Yilmaz M, Taninmis H, Kara E, Ozagari A, Unsal A. Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. Osteoporos Int 2012; 23: 2059-2062. doi: 10.1007/s00198-011-1836-2
8. Nagahama M, Sica DA. Pamidronate-induced kidney injury in a patient with metastatic breast cancer. Am J Med Sci 2009; 338: 225-228. doi: 10.1097/MAJ.0b013e318184e741
9. Takei T, Itabashi M, Tsukada M, et al. Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimalchange nephrotic syndrome. Intern Med 2010; 49: 2065-2070. doi: 10.2169/internalmedicine.49.3707
10. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-1406. doi: 10.1093/ndt/gfh832
11. Yahya TM, Dhanyamraju S, Harrington TM, Prichard JW. Spontaneous resolution of lupus nephritis following withdrawal of etanercept. Ann Clin Lab Sci 2013; 43: 447-449.
12. Korsten P, Sweiss NJ, Nagorsnik U, et al. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis 2010; 56: e17-e21. doi: 10.1053/j.ajkd.2010.08.019
13. Chin G, Luxton G, Harvey JM. Infliximab and nephrotic syndrome. Nephrol Dial Transplant 2005; 20: 2824-2826. doi: 10.1093/ndt/gfi180
14. Den Broeder AA, Assmann KJ, van Riel PL, Wetzels JF. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. Neth J Med 2003; 61: 137-141.
15. Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients’ management. Nat Rev Nephrol 2013; 9: 154-169. doi: 10.1038/nrneph.2012.289
16. Munyentwali H, Bouachi K, Audard V, et al. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease. Kidney Int 2013; 83: 511-516. doi: 10.1038/ki.2012.444
17. Leiper K, Martin K, Ellis A, et al. Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 2011; 60: 1520-1526. doi: 10.1136/gut.2010.225482